EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business ...

Novo is open to considering a direct listing of its shares on the New York Stock Exchange, chief executive officer Mike Doustdar told the Financial Times. The shift to listing shares directly would ...

Clinical data harmonization is the real bottleneck standing between life sciences companies and AI's transformative potential. The life sciences industry is navigating a pivotal transition in 2026.

How to help drug manufacturers navigate complex market factors to reach more patients is a challenge nearly every company faces. That’s why market access strategies continue to be top of mind in the ...

Jen leads EVERSANA’s market access, pricing, and reimbursement strategies, helping life sciences innovators overcome barriers to drug access and affordability. With more than two decades of leadership ...

A key factor of this is the growing acceptance of RWD in trial design. The agency hopes that by allowing RWD collected by qualified research institutions, drug developers will not only be able to move ...

Chief executives from nine of Europe's largest drugmakers are calling on the European Union (EU) and its member states to ...

Nine major European drugmakers warn the region risks losing pharma investment, Novartis licenses a preclinical radioligand ...

The best CI partner isn't the one with the most data — it's the one willing to tell you your assumptions are wrong. Pharma ...

The FDA's movement to encourage real-world data use through downstream acceptance is, in effect, a call to action for ...

FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...